Can Sex Hormone-Binding Globulin (SHBG) be decreased in pituitary adenoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Yes, sex hormone-binding globulin (SHBG) levels can be decreased in patients with pituitary adenomas, particularly those that secrete growth hormone (GH) or prolactin.

Background

This decrease occurs because these hormonal imbalances affect liver production of SHBG. In growth hormone-secreting adenomas (acromegaly), excess GH and IGF-1 can directly suppress SHBG synthesis in the liver, as suggested by the relationship between GH levels and IGF1 concentrations 1.

Clinical Significance

Similarly, prolactinomas can lead to hypogonadism with reduced estrogen levels, which normally stimulate SHBG production. The decreased SHBG is clinically significant because it increases free (bioavailable) testosterone and estrogen in circulation, potentially causing symptoms like menstrual irregularities in women or altered sexual function in both sexes.

Diagnosis and Management

Treatment of the underlying pituitary adenoma through surgery, medication (such as dopamine agonists for prolactinomas or somatostatin analogs for GH-secreting tumors), or radiation therapy typically helps normalize SHBG levels as the hormonal environment returns to balance. According to the consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence, dynamic pituitary assessment of possible hypofunction and hyperfunction of other anterior pituitary hormones is recommended 1.

Key Considerations

Key considerations in managing pituitary adenomas include:

  • Monitoring GH and IGF1 levels at baseline and during follow-up 1
  • Assessing for hypofunction of other pituitary hormones caused by tumour mass compression or prolactin co-secretion 1
  • Evaluating for syndromic diseases associated with pituitary adenomas, such as Carney complex, McCune–Albright syndrome, and MEN1 or MEN1-like disease 1
  • Offering biochemical screening for pituitary hormone excess to all CYP with these syndromes 1

From the Research

SHBG Levels in Pituitary Adenoma

  • The relationship between Sex Hormone Binding Globulin (SHBG) levels and pituitary adenoma is complex, with some studies suggesting that SHBG can be affected by the presence of a pituitary tumor 2.
  • In one case study, a patient with a TSH-secreting pituitary adenoma was found to have elevated SHBG levels, which supported the diagnosis of TSHoma 3.
  • However, there is no direct evidence to suggest that SHBG levels can be decreased in pituitary adenoma, and more research is needed to fully understand the relationship between SHBG and pituitary tumors.

Factors Affecting SHBG Levels

  • SHBG levels can be influenced by various factors, including metabolic diseases, endocrine disorders, and certain medications 2.
  • Body mass index (BMI) and insulin-like growth factor 1 (IGF-1) levels have been identified as potential risk factors for discordant GH and IGF-1 levels after pituitary surgery in acromegalic patients 4.
  • The primary treatment of acromegaly, including transsphenoidal adenomectomy and medical management with dopamine agonists and somatostatin analogs, can also impact SHBG levels 5, 6.

Clinical Significance of SHBG

  • SHBG has been recognized as a useful clinical marker for certain pathological states, including obesity, metabolic syndrome, and polycystic ovary syndrome 2.
  • Further research is needed to fully understand the clinical significance of SHBG and its potential role in the diagnosis and management of pituitary adenoma and other endocrine disorders.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.